Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx, Axon to Develop Scanning Tool for Protein Biochips

NEW YORK, April 12 - Zyomyx and Axon Instruments have agreed to jointly develop scanning instrumentation for acquiring and analyzing data from Zyomyx's protein biochips, the companies said Thursday.

Zyomyx, which has said it plans to release a beta version of its chip later this year, will work with Axon to build several generations of scanning products and evaluate fluorescence and non-fluorescence platforms. The companies did not disclose financial details.

"Zyomyx strongly impressed us with their advanced protein biochip technology, so we're pleased that they have chosen Axon to co-develop biochip scanning and imaging platforms," said David Wellis, Axon's vice president of functional genomics, in a statement. "The collaboration with Zyomyx is an important part of Axon's strategic plan to expand our functional genomics product line into proteomics."

Based in Hayward, Calif., Zyomyx is developing high density protein chips using a unique surface chemistry derived from high resolution microscopy. The company also has alliances with Cambridge Antibody Technology, Dyax, Fujirebio, and MDS Proteomics.

Axon is a Union City, Calif.-based company that develops instrumentation for the neuroscience, neurosurgery, and genomics research markets.  
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.